| Literature DB >> 10749111 |
J L Wang1, Z J Zhang, S Choksi, S Shan, Z Lu, C M Croce, E S Alnemri, R Korngold, Z Huang.
Abstract
Bcl-2 is a potent suppressor of apoptosis, and its overexpression contributes to tumorigenesis in many types of human cancers. To test the possibility of modulating Bcl-2 function as an anticancer strategy, a cell permeable Bcl-2 binding peptide, cell permeable moiety (cpm)-1285, was designed by chemically attaching a fatty acid to a peptide derived from the proapoptotic protein Bad. cpm-1285 entered HL-60 tumor cells, bound Bcl-2 protein, and induced apoptosis in vitro. In contrast, cpm-1285 had little effect on normal human peripheral blood lymphocytes. Furthermore, cpm-1285 had in vivo activity in slowing human myeloid leukemia growth in severe combined immunodeficient mice. These results demonstrate a novel approach for therapeutic intervention of tumor growth in vivo with small molecule inhibitors of Bcl-2.Entities:
Mesh:
Substances:
Year: 2000 PMID: 10749111
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701